DoW Breast Cancer, Breakthrough Award Levels 1 and 2
Dept. of the Army -- USAMRAA
Funding Amount
$31,800,000 total
Deadline
July 8, 2026
37 days left
Grant Type
federal
Overview
DoW Breast Cancer, Breakthrough Award Levels 1 and 2
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Levels 1 and 2. Distinctive Features: · This funding mechanism allows for applications submitted under Funding Level 1 or Funding Level 2. Funding Level 2 also includes a Population Science Studies option. With compelling justification, population science studies may request higher levels of funding and an additional year in the period of performance. · This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.
Details
- Agency: Dept. of the Army -- USAMRAA
- Department: Department of Defense
- Opportunity #: HT942526BCRPBTA12
- Total Funding: $31,800,000
- Expected Awards: 18
- Instrument: grant
Eligibility
Eligible Applicant Types
Focus Areas & Funding Uses
Fields of Work
Categories
Browse similar grants by category
Related Grants
Similar grants from this funder and related organizations
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Up to $350,000
Deadline
September 7, 2026
Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Up to $499,000
Deadline
September 7, 2026
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
National Institutes of Health
Amount
Up to $200,000
Deadline
September 7, 2026
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
September 25, 2026
Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Up to $475,000
Deadline
Closed
Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
Closed
Ready to apply for DoW Breast Cancer, Breakthrough Award Levels 1 and 2?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found DoW Breast Cancer, Breakthrough Award Levels 1 and 2. Now let's win it.